Estimating the potential savings with vagus nerve stimulation for treatment-resistant depression: a payer perspective^*

References

• Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386–921. Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386–92
   PubMed Web of Science ®Google Scholar
• Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 16:26–312. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 16:26–31
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465–753. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465–75
   PubMed Web of Science ®Google Scholar
• Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on healthcare utilization and costs. J Clin Psychiatry 2002;63:963–714. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on healthcare utilization and costs. J Clin Psychiatry 2002;63:963–71
   PubMed Web of Science ®Google Scholar
• Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341–75. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341–7
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004;22:363–736. Greenberg PE, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004;22:363–73
   PubMed Web of Science ®Google Scholar
• Koopmans GT, Donker MCH, Rutten FHH. Length of hospital stay and health services use of medical inpatients with comorbid noncognitive mental disorders: a review of the literature. Gen Hosp Psychiatry 2005;27:44–567. Koopmans GT, Donker MCH, Rutten FHH. Length of hospital stay and health services use of medical inpatients with comorbid noncognitive mental disorders: a review of the literature. Gen Hosp Psychiatry 2005;27:44–56
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905–178. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905–17
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51 Suppl 6:39–479. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51 Suppl 6:39–47
   PubMedGoogle Scholar
• Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 16:5–910. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 16:5–9
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Shon S, Crismon ML, et al. Texas implementation of medication algorithms (TIMA) Guidelines for treating major depressive disorder. http://www.dshs.state.tx.us/mhprograms/pdf/timaMDDman.pdf [Last accessed 12 May 2008]11. Trivedi MH, Shon S, Crismon ML, et al. Texas implementation of medication algorithms (TIMA) Guidelines for treating major depressive disorder. http://www.dshs.state.tx.us/mhprograms/pdf/timaMDDman.pdf [Last accessed 12 May 2008]
   Google Scholar
• Treatment choices throughout STAR*D. www.nimh.nih.gov/health/trials/practical/stard/stard-treatment-flowchart.pdf [Last accessed 12 May 2008]12. Treatment choices throughout STAR*D. www.nimh.nih.gov/health/trials/practical/stard/stard-treatment-flowchart.pdf [Last accessed 12 May 2008]
   Google Scholar
• Finch RA, Phillips K. Center for Prevention and Health Services: an employer's guide to behavioral health services: a roadmap and recommendations for evaluating, designing, and implementing behavioral health services. Washington, DC: National Business Group on Health; 2005. Data available at: http://www.wbgh.org/pdfs/fullreport_behavioralhealthservices.pdf [Last accessed 1 March 2008]13. Finch RA, Phillips K. Center for Prevention and Health Services: an employer's guide to behavioral health services: a roadmap and recommendations for evaluating, designing, and implementing behavioral health services. Washington, DC: National Business Group on Health; 2005. Data available at: http://www.wbgh.org/pdfs/fullreport_behavioralhealthservices.pdf [Last accessed 1 March 2008]
   Google Scholar
• Rost K, Smith JL, Dickinson M. The effect of improving primary care depression management on employee absenteeism and productivity: a randomized trial. Med Care 2004;42:1202–1014. Rost K, Smith JL, Dickinson M. The effect of improving primary care depression management on employee absenteeism and productivity: a randomized trial. Med Care 2004;42:1202–10
   PubMed Web of Science ®Google Scholar
• Simon GE, Katon WJ, Lin EH, et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry 2007;64:65–7215. Simon GE, Katon WJ, Lin EH, et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry 2007;64:65–72
   PubMed Web of Science ®Google Scholar
• Nahas Z, Marangell LB, Husain MM, et al. J Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005;66:1097–10416. Nahas Z, Marangell LB, Husain MM, et al. J Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005;66:1097–104
   PubMed Web of Science ®Google Scholar
• Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005;58:355–6317. Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005;58:355–63
   PubMed Web of Science ®Google Scholar
• George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005;58:364–7318. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005;58:364–73
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Manon-Espaillat R, Ristanovic R, et al. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First international vagus nerve stimulation study group. Epilepsia 1994;35:616–2619. Ben-Menachem E, Manon-Espaillat R, Ristanovic R, et al. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First international vagus nerve stimulation study group. Epilepsia 1994;35:616–26
   PubMed Web of Science ®Google Scholar
• Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 1998;51:48–5520. Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 1998;51:48–55
   PubMed Web of Science ®Google Scholar
• Morris GL, Mueller WM. Vagus Nerve Stimulation Study Group (E01-E05). Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. Neurology 1999;53:1731–521. Morris GL, Mueller WM. Vagus Nerve Stimulation Study Group (E01-E05). Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. Neurology 1999;53:1731–5
   PubMed Web of Science ®Google Scholar
• Boon P, D’Have M, Van Walleghem P, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia 2002;43:96–10222. Boon P, D’Have M, Van Walleghem P, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia 2002;43:96–102
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Hellstrom K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology 2002;59 Suppl 4:S44–723. Ben-Menachem E, Hellstrom K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology 2002;59 Suppl 4:S44–7
   PubMed Web of Science ®Google Scholar
• Bernstein AL, Barkan H, Hess T. Vagus nerve stimulation therapy for pharmacoresistant epilepsy: effect on health-care utilization. Epilepsy Behav 2007;10:134–724. Bernstein AL, Barkan H, Hess T. Vagus nerve stimulation therapy for pharmacoresistant epilepsy: effect on health-care utilization. Epilepsy Behav 2007;10:134–7
   PubMed Web of Science ®Google Scholar
• Boon P, Vonck K, D’Have M, et al. Cost-benefit of vagus nerve stimulation for refractory epilepsy. Acta Neurol Belg 1999;99:275–8025. Boon P, Vonck K, D’Have M, et al. Cost-benefit of vagus nerve stimulation for refractory epilepsy. Acta Neurol Belg 1999;99:275–80
   PubMed Web of Science ®Google Scholar
• Corey-Lisle PK, Birnbaum HG, Greenberg PE, et al. Identification of a claims data ‘signature’ and economic consequences for treatment-resistant depression. J Clin Psychiatry 2002;63:717–2626. Corey-Lisle PK, Birnbaum HG, Greenberg PE, et al. Identification of a claims data ‘signature’ and economic consequences for treatment-resistant depression. J Clin Psychiatry 2002;63:717–26
   PubMed Web of Science ®Google Scholar
• 12 Months Percent Change Medical Care, Consumer Price Index, US Bureau of Labor Statistics.: 2007. Series Id: CWUROOOOSAM. Data Available at: http://data.bls.gov. [Last accessed 1 April 2008]27. 12 Months Percent Change Medical Care, Consumer Price Index, US Bureau of Labor Statistics.: 2007. Series Id: CWUROOOOSAM. Data Available at: http://data.bls.gov. [Last accessed 1 April 2008]
   Google Scholar
• Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 16:10–1728. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 16:10–17
   PubMed Web of Science ®Google Scholar
• Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005;58:347–5429. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005;58:347–54
   PubMed Web of Science ®Google Scholar
• Physician's Manual. VNS Therapy Pulse Model 102 Generator and VNS Therapy Pulse Duo Model 102R Generator. Data Available at: http://www.vnstherapy.com/depression/hcp/Manuals/default.aspx [Last accessed 28 January 2008]30. Physician's Manual. VNS Therapy Pulse Model 102 Generator and VNS Therapy Pulse Duo Model 102R Generator. Data Available at: http://www.vnstherapy.com/depression/hcp/Manuals/default.aspx [Last accessed 28 January 2008]
   Google Scholar
• Kessler RC, Greenberg PE, Mickelson KD, et al. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med 2001;43:218–2531. Kessler RC, Greenberg PE, Mickelson KD, et al. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med 2001;43:218–25
   PubMed Web of Science ®Google Scholar
• Langa KM, Valenstein MA, Fendrick AM, et al. Extent and cost of informal caregiving for older Americans with symptoms of depression. Am J Psychiatry 2004;161:857–6332. Langa KM, Valenstein MA, Fendrick AM, et al. Extent and cost of informal caregiving for older Americans with symptoms of depression. Am J Psychiatry 2004;161:857–63
   PubMed Web of Science ®Google Scholar
• Schulz R, Beach SR. Caregiving as a risk factor for mortality: the caregiver health effects study. JAMA 1999;282:2215–933. Schulz R, Beach SR. Caregiving as a risk factor for mortality: the caregiver health effects study. JAMA 1999;282:2215–9
   PubMed Web of Science ®Google Scholar